Loading...
XSHE
300267
Market cap995mUSD
Oct 09, Last price  
3.36CNY
1D
4.02%
1Q
2.13%
Jan 2017
-74.25%
IPO
53.76%
Name

Hunan Er-Kang Pharmaceutical Co Ltd

Chart & performance

D1W1MN
XSHE:300267 chart
P/E
—
P/S
5.96
EPS
—
Div yield, %
—
Shrs. gr., 5y
—
Rev. gr., 5y
-12.25%
Revenues
1.16b
+2.04%
157,832,491363,933,848608,416,476834,858,6441,010,838,0171,370,358,4901,755,998,9152,705,821,6232,827,885,1902,354,485,5792,354,485,5782,744,341,0052,382,275,0092,235,302,7872,235,302,7871,870,540,8101,870,540,8101,783,118,7801,139,612,2751,162,909,633
Net income
-380m
L+1.73%
22,750,49066,462,150117,811,939151,906,924192,929,453288,288,648604,578,677795,351,361522,456,317216,579,339216,579,344158,755,207192,306,4240-791,202,02645,944,93045,944,933-195,322,350-373,371,430-379,817,624
CFO
261m
+56.85%
209,79810,181,90742,471,66475,733,19284,021,539174,221,200175,382,420518,955,781486,495,536687,211,143123,894,781445,815,848178,527,34192,683,406281,019,942148,420,737166,691,706261,460,359
Dividend
Jun 09, 20230.03 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Hunan Er-Kang Pharmaceutical Co., Ltd is a pharmaceutical company that manufactures and sells active pharmaceutical ingredients (APIs), completed drug formulations, and pharmaceutical excipients, serving both the Chinese domestic market and international clients. Its API portfolio features substances such as glycerin, dilute hydrochloric acid, sulbenicillin sodium, calamine powder, sulfadiazine, sulphaguanidine, TMP, and resorcinol. The company's principal finished medications include sulbenicillin sodium for injection and compound liquorice tablets. For conventional pharmaceutical excipients, it provides items like pharmaceutical glycerin, medicinal ethanol, medicinal propylene glycol, medicinal sodium hydroxide, and sucrose. Furthermore, its advanced pharmaceutical excipient offerings encompass hydroxypropyl starch empty capsules, hydroxypropyl starch soft capsules, and citrate along with its related product series. The firm was established in 2003 and is headquartered in Liuyang, China.

Key people

Fangwen Shuai
Chairman of the Board · since 2015
Jishun Gu
Deputy General Manager, Secretary of the Board · since 2020
Xiangyan Shi
Deputy General Manager, Director · since 2020
Hui Wang
Deputy General Manager · since 2019
Zhengchun Zheng
Deputy General Manager · since 2025
Jiang Xiao
Chief Engineer · since 2022
Qingrong Sun
General Manager, Director · since 2022
Xun Zhao
Chief Financial Officer, Staff Elected Director · since 2025
Independent Director · since 2025
Xue Tan
Independent Director · since 2022
Yong Wu
Independent Director · since 2025
IPO date
Sep 27, 2011
Employees
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
长沙市浏阳经济开发区康平路167号
长沙市, HN 100000
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122019‑002018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT